

Statement of Standalone Unaudited Results for the Quarter and half year ended 30.09.2017

(in Rs.)

Sr. No.	Particulars	Quarter Ended			Half Year Ended	
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
I.	Revenue from operations	33719949	26061713	0	59781662	0
II.	Other income	44371	200880	150000	245251	300000
III.	Total Income (I+II)	33764320	26262593	150000	60026913	300000
IV.	Expenses					
	(a) Cost of materials consumed	13736054	24823650	0	38559704	0
	(b) Purchase of stock-in-trade	0	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	6674743	-8477631	0	-1802888	0
	(d) Employee benefits expense	6942345	5090282	0	12032627	0
	(e) Finance Costs	186881	0	0	186881	0
	(f) Depreciation and amortisation expense	2724000	2487000	0	5211000	0
	(g) Other expenses	4601075	4430804	140706	9031879	249623
	Total expenses (IV)	34865098	28354105	140706	63219203	249623
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-1100778	-2091512	9294	-3192290	50377
VI	Exceptional Items	0	0	0	0	0
VII	Profit/ (Loss) before tax (V-VI)	-1100778	-2091512	9294	-3192290	50377
VIII	Tax expense:	0	0	0	0	0
	(1) Current tax	0	0	0	0	0
	(2) Deferred tax	0	0	0	0	0
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-1100778	-2091512	9294	-3192290	50377
X	Profit/(loss) from discontinued operations	0	0	0	0	0
XI	Tax expense of discontinued operations	0	0	0	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0	0
XIII	Profit (Loss) for the period (IX+XII)	-1100778	-2091512	9294	-3192290	50377
XIV	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0
	B. (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-1100778	-2091512	9294	-3192290	50377
XVI	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	37413000
XVII	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):					
	(a) Basic	-0.29	-0.56	0.00	-0.85	0.01
	(b) Diluted					



Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 08.12.2017.
2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 30th September, 2017
3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
4. Statement of Unaudited Financial Results of the company for the Quarter and half year ended 30th September, 2017, in the prescribed format under Schedule III of Companies Act, 2013
5. The figures for the previous period have been regrouped wherever necessary.
6. The company has opted to avail the relaxations provided by the SEBI, vide its circular no. CIR/CFD/FAC/62/2016 dated 5th July, 2016, as available to listed entities. Accordingly, the company has provided IND AS compliant financial results only for corresponding quarter/half year ended 30.09.2016. Thus, in accordance to the relaxation provided in aforesaid circular by SEBI, the results for the quarter/half year ended 30th September, 2016 have not been subject to Limited Review or audit. However, management has exercised necessary due diligence to ensure that the financial results provide a true and fair view.
7. The figures stated above for quarter ending 30th September, 2016 are as per Ind AS and in complete reconciliation with previously applicable GAAP. No difference has been observed between the same. For reference reconciliation table is provided below.

Reconciliation of Net Profit as previously reported under Indian GAAP to Ind-AS for the Quarter and half year ended 30th Sep, 2016 is as under:

Particulars	Quarter ended 30.09.2016	Half Year ended 30.09.2016
Net Profit/Loss as per previous GAAP (IND GAAP)	9294	50377
Adjustments	NIL	NIL
Net Profit/Loss as per IND AS	9294	50377

FOR, PARMAX PHARMA LIMITED

Alkesh Gosalia

Alkesh Gosalia
Director



Place Hadamtala (Rajkot)
Date: 08.12.2017

Statement of Assets and Liabilities as at 30.09.2017

Sr. No.	Particulars	As at 30.09.2017 (Unaudited)
I.	Assets	
1	Non-current assets	
	(a) Property, Plant and Equipment	58851119
	(b) Capital work-in-progress	0
	(c) Investment Property	0
	(d) Goodwill	0
	(e) Other Intangible assets	0
	(f) Intangible assets under development	0
	(g) Biological Assets other than bearer plants	0
	(h) Financial Assets	0
	(i) Investments	6000
	(ii) Trade receivables	0
	(iii) Loans	790899
	(i) Deferred tax assets (net)	0
	(j) Other non-current assets	11974466
	Total Non-Current Assets	71622484
2	Current assets	
	(a) Inventories	29743478
	(b) Financial Assets	0
	(i) Investments	0
	(ii) Trade receivables	20402523
	(iii) Cash and cash equivalents	108785
	(iv) Bank balances other than (iii) above	1872725
	(v) Loans	20393067
	(vi) Others (to be specified)	0
	(c) Current Tax Assets (Net)	0
	(d) Other current assets	0
	Total Current Assets	72520578
	Total Assets	144143062
II.	EQUITY AND LIABILITIES	
1	Equity	
	(a) Equity Share capital	44511500
	(b) Other Equity	0
	Total Equity	44511500
2	LIABILITIES	
i.	Non-current liabilities	
	(a) Financial Liabilities	0
	(i) Borrowings	17064979
	(ii) Trade payables	0
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0
	(b) Provisions	0
	(c) Deferred tax liabilities (Net)	0
	(d) Other non-current liabilities	0
	Total of Non-Current Liabilities	17064979
ii.	Current liabilities	
	(a) Financial Liabilities	0
	(i) Borrowings	0
	(ii) Trade payables	81533719
	(iii) Other financial liabilities (other than those specified in item (c))	-2143054
	(b) Other current liabilities	68042
	(c) Provisions	3073876
	(d) Current Tax Liabilities (Net)	34000
	Total of Current Liabilities	82566583
	Total Equity and Liabilities	144143062



BHARAT A. SHAH

B.Com. F.C.A. (DISA)

B. A. SHAH ASSOCIATES

Chartered Accountants

209 Sapphire, 2nd Floor, 21/25 – B, New Jagnath Plot, Rajkot. – 360 001. Ph.: 0281 - 2468261

**Auditor's Limited Review Report
On Unaudited Financial Results**

To

**The Board of Directors,
PARMAX PHARMA LIMITED**

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and six months ended 30 September 2017 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on 8th December 2017. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRS:) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B A SHAH ASSOCIATES

Chartered Accountants

FRN.: 109493W

Bharat A Shah

BHARAT SHAH

PROPRIETOR

M. NO.034222



Date: 08.12.2017

Place: Rajkot